ruxolitinib

Also Known As:

3R)-3-cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile; INC-424; INC424; INCA24; INCB-018424; INCB-018424 phosphate; INCB-018424 salt; INCB-18424; INCB-18424 phosphate; INCB018424; INCB018424 phosphate; Jakafi; Jakavi; opzelura; ruxolitinib (as phosphate); ruxolitinib monophosphate; ruxolitinib phosphate

Networked: 1604 relevant articles (313 outcomes, 351 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Verstovsek, Srdan: 116 articles (06/2022 - 01/2009)
2.	Vannucchi, Alessandro M: 47 articles (07/2022 - 03/2012)
3.	Mesa, Ruben A: 45 articles (01/2022 - 09/2009)
4.	Harrison, Claire N: 37 articles (01/2022 - 07/2013)
5.	Passamonti, Francesco: 35 articles (07/2022 - 06/2011)
6.	Palandri, Francesca: 34 articles (07/2022 - 03/2015)
7.	Breccia, Massimo: 31 articles (06/2022 - 11/2014)
8.	Kiladjian, Jean-Jacques: 30 articles (01/2022 - 03/2012)
9.	Bose, Prithviraj: 29 articles (01/2022 - 03/2016)
10.	Benevolo, Giulia: 28 articles (01/2022 - 01/2016)

Related Diseases

1.	Primary Myelofibrosis (Myelosclerosis) 01/01/2017 - "Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. " 10/01/2021 - "Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study." 12/01/2013 - "Clinical trials have demonstrated that Ruxolitinib has good therapeutic efficacy for the treatment of myelofibrosis and is currently FDA approved for the treatment of advanced stages of this disease. " 11/01/2019 - "Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. " 01/01/2018 - "Treatment with ruxolitinib, a selective JAK1/2 inhibitor, has significantly improved the lives of patients with myelofibrosis. "
2.	Splenomegaly 01/01/2017 - "Ruxolitinib, an oral JAK1/2 inhibitor, is highly effective in ameliorating systemic symptoms and reducing splenomegaly. " 01/01/2009 - "The most developed among them is INCB018424, which has demonstrated noteworthy clinical activity, with a rapid and profound reduction in splenomegaly and associated improvement in constitutional symptoms in MF patients receiving 10-25 mg orally twice daily, continuously. " 01/01/2021 - "Low numbers of PD1+/CD4+ and PD1+/CD8+ cells were associated with complete resolution of palpable splenomegaly and improved survival rate, suggesting that low levels of exhausted T cells confer a favorable response to ruxolitinib treatment." 07/01/2013 - "While not a curative option, ruxolitinib offers great palliative potential and results in significant reduction in splenomegaly and improvement in constitutional symptoms in the majority of treated patients, thus improving their quality of life and performance status. " 01/01/2018 - "Other than HSCT options, ruxolitinib ameliorates splenomegaly and MF-associated symptoms and provides an overall survival benefit in PMF patients with intermediate-2 or high risk. "
3.	Neoplasms (Cancer) 02/01/2015 - "Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes." 01/01/2021 - "The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with myeloproliferative neoplasms (MPN). " 02/09/2018 - "Importantly, ruxolitinib significantly inhibited tumor progression by bioluminescence (p < 0.05) and significantly improved survival in HL (p = 0.0001) and PMBL (p < 0.0001) xenograft NSG mice. " 12/17/2018 - "The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms." 07/28/2015 - "The JAK/STAT signalling pathway provides an example of this paradigm in haematological malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clinically effective JAK2 inhibitors, such as ruxolitinib. "
4.	COVID-19 05/01/2022 - "We assessed whether treatment with the JAK1/JAK2 inhibitor ruxolitinib would be beneficial in patients with COVID-19 admitted to hospital. " 01/01/2021 - "Here, we report 3 severe COVID-19 cases, which achieved rapid and sustained improvement in outcome with the use of ruxolitinib, a JAK/STAT pathway inhibitor." 07/01/2020 - "Treatment with ruxolitinib plus standard-of-care was not associated with significantly accelerated clinical improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clinical improvement. " 02/01/2021 - "The selective JAK1/2 inhibitor ruxolitinib has shown promising results in the context of GVHD, and different trials are currently underway in patients with severe COVID-19; nevertheless, no clinical observation of safety or efficacy of treatment with ruxolitinib in this context has been published yet. " 01/01/2023 - "In conclusion, ruxolitinib proved to be safe and effective in a cohort of COVID-19 patients with defined hyperinflammation."
5.	Graft vs Host Disease (Graft-Versus-Host Disease) 01/01/2020 - " covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD. " 05/23/2022 - "Tongue graft-versus-host disease: remission with ruxolitinib." 11/21/2023 - "Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease." 01/01/2023 - "Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease." 01/01/2023 - "JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK/STAT and ROS-MAPK/NF-κB signalling pathways in acute graft-versus-host disease."

Related Drugs and Biologics

1.	Janus Kinase Inhibitors
2.	Janus Kinases
3.	fedratinib
4.	Steroids
5.	tofacitinib
6.	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaene
7.	Hydroxyurea (Hydrea)
8.	Cytokines
9.	ruxolitinib
10.	Janus Kinase 1

Related Therapies and Procedures

1.	Therapeutics
2.	Hematopoietic Stem Cell Transplantation
3.	Artificial Respiration (Mechanical Ventilation)
4.	Salvage Therapy
5.	Stem Cell Transplantation